In addition, some authors have concluded that PARP-1 inhibition could be useful in a broader range of breast cancers, including ER+ breast cancers (not necessarily mutated in the BRCA DNA repair associated genes) [14,39]. The gene discussed is PARP1; the disease is breast carcinoma.